PRME
Prime Medicine Inc.
Is PRME Halal?
Prime editing technology — bioethics consultation needed.
What You Should Know
Next-gen CRISPR with fewer errors. Its March 31, 2026 Form 10-Q reports $294.730 million of assets, $114.512 million of operating-lease liabilities, $64.106 million of cash, $71.391 million of debt securities and $0.856 million of quarterly collaboration revenue. Debt/assets is 38.85%, liquidity/assets is 45.97% and disclosed interest income is 119.28% of revenue; the examined financial screens fail. Same ethical considerations as other gene-editing firms. Consult scholar.
⚠️ Concerns
- •Gene editing ethics
- •Debt, liquidity and income screens fail
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
114.512 / 294.73
135.497 / 294.73
64.106 / 294.73
1.021 / 0.856
- Financial
- Fails
- Overall
- Fails
Debt/assets is 38.85%, liquidity/assets is 45.97% and disclosed interest income is 119.28% of revenue; the examined financial limits fail.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 38.85% and liquidity/assets is 45.97%, above the examined MSCI total-assets limits; receivables-plus-cash/assets is 21.75%.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 38.85% and liquidity/assets is 45.97%, above the examined Malaysia 33% limits. This calculation is not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A properly licensed and reproducible historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
Prime Medicine develops prime-editing therapies for genetic disease. Therapeutic healthcare is generally permissible, while gene-editing boundaries, licensing and program allocation require qualified scholarly review.
Limitation: The filing does not provide a universal prohibited-activity numerator across collaborations and therapeutic programs.
Purification
Prime Medicine discloses $1.021 million of interest income, but no scholar-approved purification percentage is asserted for the operating business.
Inputs, assumptions and primary sources
- Amounts are USD millions from Prime Medicine's March 31, 2026 Form 10-Q.
- Conservative debt is the $114.512 million current and noncurrent operating-lease liability; no separate borrowing balance is tagged in the filing facts.
- Cash and cash equivalents are $64.106 million and current available-for-sale debt securities are $71.391 million; no separate accounts-receivable balance is tagged.
- Quarterly collaboration revenue is $0.856 million and disclosed interest income is $1.021 million, or 119.28% of revenue.
- Prime editing therapeutics are generally permissible in the retained qualitative analysis, but gene-editing boundaries and clinical-program allocation remain case-dependent.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →